US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,792.56

-14.9202-0.53%

Number of Gainers:1

Number of Losers:4

Number of Flat:- -

PE:- -

High:2,825.24

Open:2,808.86

Low:2,773.89

Close:2,807.48

Volume:6.51M

Turnover:94.32M

Market Cap:46.58B

Float Cap:43.49B

Loading ...

Veru Initiated at Buy by WestPark Capital

Veru initiated with a Buy at WestPark Capital

Dare Bioscience - Notified by NASDAQ of Non-Compliance with Minimum Bid Price Requirement - SEC Filing

THOMSON REUTERS

Daré Bioscience Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price

Teva: Additional Analyses Found That Common Concurrent Psychiatric Conditions Did not Negatively Impact Ecopipam's Efficacy or Safety

THOMSON REUTERS

Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates

MT Newswires Live

Teva initiated with a Buy at TD Cowen

Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates

MT Newswires Live

MannKind (MNKD) Jumps On Fresh Momentum As Fair Value Stays In Focus

Simply Wall St.

Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness

Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist

NYSE Order Imbalance 18799.0 Shares on Buy Side

THOMSON REUTERS

Teva Reports FDA Approval for Degevma

MT Newswires Live

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live

Daré Bioscience Wins New US Patent Covering Topical Lopinavir-Ritonavir Formulation for DARE-HPV Program

Dare Bioscience Announces New U.S. Patent Strengthening Dare-Hpv Program as a Potential First FDA-Approved Pharmacologic Treatment for Hpv Infection

THOMSON REUTERS

NYSE Order Imbalance 23191.0 Shares on Buy Side

THOMSON REUTERS

Teva Releases Q3 2026 Aide Memoire

THOMSON REUTERS

Evofem Contracts Second Manufacturer for Phexxi Contraceptive Gel

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2792.5562,"timestamp":1791402220880,"preClose":2807.4763,"halted":0,"volume":6505354,"delay":0,"changeRate":-0.005314,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-14.920166,"latestTime":"10-07 15:43:42 EDT","open":2808.8574,"high":2825.2393,"low":2773.8916,"amount":94323112.61793,"amplitude":0.01829,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791403200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.156954,"peRate":75.903403,"turnoverRate":0.00453,"increases":1,"decrements":4,"flats":0,"marketCap":46582964333,"floatMarketCap":43493720242},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2825.2393,"amplitude":0.01829,"preClose":2807.4763,"low":2773.8916,"pbRate":"6.156954","latestPrice":2792.5562,"volume":6505354,"delay":0,"open":2808.8574,"prevYearClose":2379.9924,"prevWeekClose":2838.5862,"prevMonthClose":2843.1685,"prevQuarterClose":2843.1685,"fiveDayClose":2843.1685,"twentyDayClose":2769.5986,"sixtyDayClose":2403.0154,"secType":"PLATE","market":"US","turnoverRate":0.00453,"peRate":75.903403,"marketCap":46582964333,"floatMarketCap":43493720242,"timestamp":1791402220880,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":1,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673068898","title":"Veru Initiated at Buy by WestPark Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068898?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:01","pubTimestamp":1791309660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERU/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4557","BK4183","VERU","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706884","title":"Veru initiated with a Buy at WestPark Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706884?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:40","pubTimestamp":1791308410,"startTime":"0","endTime":"0","summary":"WestPark Capital initiated coverage of Veru (VERU) with a Buy rating and $28 price target Lead asset enbosarm has completed 27 clinical trials acro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veru-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veru-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","BK4584","BK4183","BK4007","BK4557","VERU","IDNA","NVIB","HYLG","BMED","DBB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672713746","title":"Dare Bioscience - Notified by NASDAQ of Non-Compliance with Minimum Bid Price Requirement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2672713746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672713746?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:03","pubTimestamp":1790971400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672467627","title":"Daré Bioscience Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2672467627","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672467627?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:02","pubTimestamp":1790971339,"startTime":"0","endTime":"0","summary":"Daré Bioscience gets Nasdaq notice after shares trade below $1 minimum bid priceDaré Bioscience received a Nasdaq notice for failing the $1.00 minimum bid price rule after 30 consecutive business days","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL5xvVQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672711984","title":"Teva: Additional Analyses Found That Common Concurrent Psychiatric Conditions Did not Negatively Impact Ecopipam's Efficacy or Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2672711984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672711984?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:00","pubTimestamp":1790942410,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0SH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEVA","BK4557","LU2324357040.USD","BK4007","LU1983299246.USD","BK4566","BK4584","BK4559","BK4596","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719237","title":"Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719237","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:27","pubTimestamp":1790940462,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  has entered into an agreement with Samsung Bioepis for the global licensing, development, and commercialization of up to six potential biosimilar candidates, the companies said Thursday.Under the deal, South Korea's Samsung Bioepis will manage the development, regulatory registration, and making of the biosimilars. Meanwhile, Teva will be in charge of commercialization in global markets, including the US, Europe, and Canada, with an option to expand to other territories, they said.The companies have confirmed two investigational biosimilar candidates, SB41, referencing Fasenra, and SB44, referencing Ilaris, the companies added.Samsung Bioepis said the parties agreed to keep the total value of the contract confidential, with the deal amount equal to or exceeding the lesser of 2.5% of Samsung Bioepis' 2025 equity or revenue","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4559","TEVA","BK4581","BK4584","BK4504","EMXC","BK4588","BK4557","BK4007","LU2324357040.USD","BK4596","IEMG","BK4566","LU1983299246.USD","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672755497","title":"Teva initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2672755497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672755497?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:35","pubTimestamp":1790847325,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome initiated coverage of Teva (TEVA) with a Buy rating and $55 price target Teva is a global biopharma company that leve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","BK4596","BK4585","BK4566","BK4588","TEVA","BK4557","LU1983299246.USD","BK4584","LU2324357040.USD","BK4007","BK4127","COWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672919755","title":"Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672919755","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672919755?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:30","pubTimestamp":1790847036,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  has entered into an agreement with Samsung Bioepis for the global licensing, development, and commercialization of up to six potential biosimilar candidates, the companies said on Thursday.Under the deal, South Korea's Samsung Bioepis will manage the development, regulatory registration, and making of the biosimilars. Meanwhile, Teva will be in charge of commercialization in global markets, including the US, Europe, and Canada, with an option to expand to other territories, Teva said.The companies have confirmed two investigational biosimilar candidates, SB41, referencing Fasenra and SB44, referencing Ilaris, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","LU1983299246.USD","BK4557","BK4559","BK4566","LU2324357040.USD","BK4550","BK4007","EMXC","BK4596","TEVA","IEMG","BK4581","BK4504","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672730503","title":"MannKind (MNKD) Jumps On Fresh Momentum As Fair Value Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2672730503","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672730503?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:12","pubTimestamp":1790831535,"startTime":"0","endTime":"0","summary":"MannKind (MNKD) has drawn fresh attention after a sharp 16.8% one day gain, followed by an 18.5% advance over the past week, raising questions about what this move implies for recent underperformance.\nThat surge comes after a tougher spell for MannKind, with the share price still down 30.4% year to date and the 1-year total shareholder return lower by 29%. The latest bounce hints at improving sentiment rather than a fully repaired long-term track record.\nScan MannKind’s sharp move despite its...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-jumps-on-fresh-momentum-as-fair-value-stays-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-jumps-on-fresh-momentum-as-fair-value-stays-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4584","BK4139","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782213","title":"Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782213","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782213?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:32","pubTimestamp":1790800320,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global bu","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","DBB","OTX.SI","BK4566","BK4557","BK6520","TEVA","BK4585","BK4007","LU2324357040.USD","BK4559","BK4584","BK4596","BK4588","BK6100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672789452","title":"Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2672789452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672789452?lang=en_us&edition=fundamental","pubTime":"2026-10-01 01:10","pubTimestamp":1790788218,"startTime":"0","endTime":"0","summary":"Liquidia’s (LQDA) Yutrepia faces a Delaware court finding of infringement of United Therapeutics’ (UTHR) ‘327 patent, pressuring Liquidia shares bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liquidia-ruling-has-positive-read-through-for-mannkind-tyvaso-dpi-says-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liquidia-ruling-has-positive-read-through-for-mannkind-tyvaso-dpi-says-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","LU1699723380.USD","LU1571399168.USD","UTHR","USRD","BK4532","LQDA","MNKD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671724230","title":"NYSE Order Imbalance 18799.0 Shares on Buy Side","url":"https://stock-news.laohu8.com/highlight/detail?id=2671724230","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671724230?lang=en_us&edition=fundamental","pubTime":"2026-09-30 03:50","pubTimestamp":1790711402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nAQN2MLD8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4585","BK4584","LU1983299246.USD","BK4588","BK4566","BK4007","BK4596","BK4559","LU2324357040.USD","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671250803","title":"Teva Reports FDA Approval for Degevma","url":"https://stock-news.laohu8.com/highlight/detail?id=2671250803","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671250803?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:25","pubTimestamp":1790627151,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said late Monday the US Food and Drug Administration has approved Degevma as a biosimilar to Xgeva.Degevma is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, it said.The drug is also indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy, Teva said.Teva said it expects to launch Degevma and Ponlimsi in the US in the coming months. Ponlimsi was approved in March.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4584","BK4588","LU1983299246.USD","BK4557","BK4596","LU2324357040.USD","LABU","BK4007","TEVA","BK4566","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","LU2324357040.USD","TEVA","BK4566","MRNY","BK4557","TECB","FRTY","MRNX","IBB","MEDI","IDNA","NVIB","TBXU","PINK","BMED","BK4007","GNMX","BK4596","GDOC","SYNB","BBP","BK4588","LABU","LFSC","IYH","RSPH","BK4585","PSCH","BK4584","LU1983299246.USD","IEIH","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670525939","title":"Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670525939","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670525939?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:49","pubTimestamp":1790610591,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical's (TEVA) Duvakitug inflammatory bowel disease drug could be validated by Merck's (MRK) upcoming Tulisokibart results, Oppenheimer said in a Friday note.Analysts said that the best ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2491049909.HKD","LU1699723380.USD","LU0124676726.USD","LU2491050071.SGD","LU0965509010.AUD","PPH","JDOC","FHLC","LU1917777945.USD","SG9999014542.SGD","LU1941712348.USD","SG9999015358.SGD","FTXH","LU2324357040.USD","LU1291159041.SGD","IE00B1BXHZ80.USD","LU0965508806.USD","LU2361044865.SGD","LU2361045086.USD","LU1430594728.SGD","LU2361044949.HKD","LU1032466523.USD","IE00BN8TJ469.HKD","LU2125154778.USD","IE0002141913.USD","LU1066051811.HKD","LU0965509101.SGD","IE0009355771.USD","LU1093756168.USD","IE00BSNM7G36.USD","BK4588","LU0859254822.USD","LU0320765646.SGD","LU1585245621.USD","LU0122379950.USD","LU0689626769.HKD","LU2357627491.SGD","BK4557","LU2106854487.HKD","BK4533","IE00BJJMRZ35.SGD","BK4007","LU0211331839.USD","LU2125909247.SGD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0162691827.USD","LU0265550359.USD","LU1571399168.USD","BK4596","LU0289739343.SGD","RXL","LU1934455277.USD","LU1941712264.USD","IE000M9KFDE8.USD","BK4584","LU0072461881.USD","LU1929549753.HKD","LU0472753341.HKD","LU2433249047.HKD","LU2112291526.USD","IE00BLSP4452.SGD","SG9999002224.SGD","LU0985320562.USD","LU2089984988.USD","BK4550","SG9999015341.SGD","IE00B2B36J28.USD","LU1037948541.HKD","LU0234572021.USD","SG9999014575.USD","SGXZ57979304.SGD","LU0868494617.USD","LU0942090050.USD","LU1023059063.AUD","LU1069347547.HKD","LU1923622614.USD","LU1162221912.USD","SG9999001440.SGD","LU1989772840.SGD","LU1093756325.SGD","SG9999001176.SGD","LU1989772923.USD","LU1116320901.HKD","LU0477156953.USD","LU0238689110.USD","LU1116320737.USD","LU0320765489.SGD","LU0130102774.USD","LU0965509283.SGD","LU0511384066.AUD","LU1061106388.HKD","LU0070302665.USD","LU2023250843.SGD","LU1974910355.USD","XLV","LU2491050154.USD","VHT","LU0106261372.USD","BK4534","PAWZ","SG9999002232.USD","LU1934455863.HKD","LU0289739699.SGD","HRTS","BMED","LU2125154935.USD","LU0006306889.USD","LU0289961442.SGD","LU0203347892.USD","SG9999013999.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1983299246.USD","LU2468319806.SGD","LU0823416689.USD","BK4585","TEVA","LU0265550946.USD","LU0069063385.USD","LU2023250504.SGD","LU0130517989.USD","LU1989771016.USD","IHE","LU0203345920.USD","LU0057025933.USD","LU1934455194.USD","LU2125909593.SGD","BK4566","GDOC","IE00B4R5TH58.HKD","IYH","LU0648001328.SGD","LU0266013472.USD","SG9999014559.SGD","MRK","LU0432979614.USD","LU0868494708.USD","BK4516","LU0980610538.SGD","LU1037948897.HKD","LU0208291251.USD","SG9999014567.USD","IE00BJT1NW94.SGD","LU1035773651.USD","LU0058720904.USD","BK4559","LU2360032135.SGD","TRUH","LU0098860793.USD","LU1201861249.SGD","LU2461242641.AUD","LU1066053197.SGD","LU1066051498.USD","IXJ","LU0861579265.USD","LU1066051225.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670523272","title":"Daré Bioscience Wins New US Patent Covering Topical Lopinavir-Ritonavir Formulation for DARE-HPV Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2670523272","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670523272?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:20","pubTimestamp":1790598019,"startTime":"0","endTime":"0","summary":"Daré Bioscience wins new US patent covering topical lopinavir-ritonavir formulation for DARE-HPV programDaré Bioscience secured U.S. Patent No. 12,678,439 covering topical lopinavir-ritonavir formulat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL3dPK6f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","BCDF","SG9999014013.SGD","LU2210149790.SGD","BK4007","BK4112","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","DARE","BK4584","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670232711","title":"Dare Bioscience Announces New U.S. Patent Strengthening Dare-Hpv Program as a Potential First FDA-Approved Pharmacologic Treatment for Hpv Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2670232711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670232711?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:20","pubTimestamp":1790598000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUA39SRQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4007","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670490255","title":"NYSE Order Imbalance 23191.0 Shares on Buy Side","url":"https://stock-news.laohu8.com/highlight/detail?id=2670490255","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670490255?lang=en_us&edition=fundamental","pubTime":"2026-09-25 03:50","pubTimestamp":1790279400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nAQN2MKNHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","LU1983299246.USD","LU2324357040.USD","BK4588","BK4585","BK4596","BK4007","BK4566","BK4584","TEVA","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669095436","title":"Teva Releases Q3 2026 Aide Memoire","url":"https://stock-news.laohu8.com/highlight/detail?id=2669095436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669095436?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:45","pubTimestamp":1790196300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUABKND6J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4596","BK4557","BK4584","BK4007","BK4566","BK4588","BK4585","TEVA","LU2324357040.USD","BK4559","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436369","title":"Evofem Contracts Second Manufacturer for Phexxi Contraceptive Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436369","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436369?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:07","pubTimestamp":1790194021,"startTime":"0","endTime":"0","summary":"Evofem contracts second manufacturer for Phexxi contraceptive gelEvofem Biosciences contracted a second pharmaceutical manufacturer to produce its PHEXX prescription contraceptive vaginal gel, expandi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL1D159v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","EVFM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}